SG11202000823WA - Thiazolopyridine derivatives as adenosine receptor antagonists - Google Patents
Thiazolopyridine derivatives as adenosine receptor antagonistsInfo
- Publication number
- SG11202000823WA SG11202000823WA SG11202000823WA SG11202000823WA SG11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonists
- adenosine receptor
- thiazolopyridine derivatives
- thiazolopyridine
- derivatives
- Prior art date
Links
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical class C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 title 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17184272 | 2017-08-01 | ||
PCT/EP2018/067797 WO2019025099A1 (en) | 2017-08-01 | 2018-07-02 | Thiazolopyridine derivatives as adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000823WA true SG11202000823WA (en) | 2020-02-27 |
Family
ID=59506176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000823WA SG11202000823WA (en) | 2017-08-01 | 2018-07-02 | Thiazolopyridine derivatives as adenosine receptor antagonists |
Country Status (23)
Country | Link |
---|---|
US (1) | US11186592B2 (en) |
EP (1) | EP3661941B1 (en) |
JP (1) | JP7336434B2 (en) |
KR (1) | KR20200035439A (en) |
CN (1) | CN110997681B (en) |
AU (1) | AU2018309265B2 (en) |
BR (1) | BR112020001978A2 (en) |
CA (1) | CA3071575A1 (en) |
DK (1) | DK3661941T3 (en) |
ES (1) | ES2940407T3 (en) |
FI (1) | FI3661941T3 (en) |
HR (1) | HRP20230251T1 (en) |
HU (1) | HUE061308T2 (en) |
IL (1) | IL272284B2 (en) |
LT (1) | LT3661941T (en) |
PL (1) | PL3661941T3 (en) |
PT (1) | PT3661941T (en) |
RS (1) | RS64035B1 (en) |
SG (1) | SG11202000823WA (en) |
SI (1) | SI3661941T1 (en) |
TW (1) | TW201920201A (en) |
WO (1) | WO2019025099A1 (en) |
ZA (1) | ZA202001295B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR117844A1 (en) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR |
CN112174943A (en) * | 2019-07-03 | 2021-01-05 | 四川大学 | Application of indole-2-ketone compound in preparation of oral bacteria prevention and treatment product |
CA3220380A1 (en) | 2021-06-07 | 2022-12-15 | Rinat ZAYNAGETDINOV | Combination treatment of cancer |
WO2024028273A1 (en) | 2022-08-02 | 2024-02-08 | Merck Patent Gmbh | Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR19990082463A (en) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | Quinazolin derivatives as vascular endothelial growth factor inhibitors |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
WO1999035147A1 (en) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
ATE303387T1 (en) | 1999-07-02 | 2005-09-15 | Eisai Co Ltd | CONDENSED IMIDAZOLE DERIVATIVES AND DRUGS FOR DIABETES MELLITUS |
EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
YU96502A (en) * | 2000-06-21 | 2006-01-16 | F. Hoffmann-La Roche Ag. | Benzothiazole derivatives |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
CA2470104C (en) | 2001-12-12 | 2015-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
US20080070932A1 (en) | 2003-04-09 | 2008-03-20 | Chi Vu | Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same |
US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
EP1636223B1 (en) * | 2003-05-19 | 2008-03-19 | F. Hoffman-la Roche AG | Benzothiazole derivatives as adenosine receptor ligands |
BRPI0414266A (en) * | 2003-09-19 | 2006-11-07 | Hoffmann La Roche | thiazolopyridine derivatives as adenosine receptor ligands |
CA2574193C (en) | 2004-07-22 | 2013-03-05 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives as adenosine receptor ligands |
KR101077295B1 (en) * | 2006-05-18 | 2011-10-26 | 에프. 호프만-라 로슈 아게 | Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists |
US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
-
2018
- 2018-07-02 WO PCT/EP2018/067797 patent/WO2019025099A1/en unknown
- 2018-07-02 RS RS20230195A patent/RS64035B1/en unknown
- 2018-07-02 FI FIEP18733649.0T patent/FI3661941T3/en active
- 2018-07-02 DK DK18733649.0T patent/DK3661941T3/en active
- 2018-07-02 EP EP18733649.0A patent/EP3661941B1/en active Active
- 2018-07-02 KR KR1020207006084A patent/KR20200035439A/en not_active Application Discontinuation
- 2018-07-02 PL PL18733649.0T patent/PL3661941T3/en unknown
- 2018-07-02 SI SI201830863T patent/SI3661941T1/en unknown
- 2018-07-02 AU AU2018309265A patent/AU2018309265B2/en active Active
- 2018-07-02 US US16/635,356 patent/US11186592B2/en active Active
- 2018-07-02 ES ES18733649T patent/ES2940407T3/en active Active
- 2018-07-02 BR BR112020001978-0A patent/BR112020001978A2/en active Search and Examination
- 2018-07-02 IL IL272284A patent/IL272284B2/en unknown
- 2018-07-02 CA CA3071575A patent/CA3071575A1/en active Pending
- 2018-07-02 HU HUE18733649A patent/HUE061308T2/en unknown
- 2018-07-02 SG SG11202000823WA patent/SG11202000823WA/en unknown
- 2018-07-02 PT PT187336490T patent/PT3661941T/en unknown
- 2018-07-02 LT LTEPPCT/EP2018/067797T patent/LT3661941T/en unknown
- 2018-07-02 HR HRP20230251TT patent/HRP20230251T1/en unknown
- 2018-07-02 JP JP2020505412A patent/JP7336434B2/en active Active
- 2018-07-02 CN CN201880050465.4A patent/CN110997681B/en active Active
- 2018-07-31 TW TW107126410A patent/TW201920201A/en unknown
-
2020
- 2020-02-28 ZA ZA2020/01295A patent/ZA202001295B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT3661941T (en) | 2023-03-16 |
CN110997681B (en) | 2022-11-15 |
WO2019025099A1 (en) | 2019-02-07 |
TW201920201A (en) | 2019-06-01 |
US11186592B2 (en) | 2021-11-30 |
AU2018309265B2 (en) | 2022-06-02 |
HRP20230251T1 (en) | 2023-04-14 |
LT3661941T (en) | 2023-04-11 |
DK3661941T3 (en) | 2023-03-13 |
IL272284A (en) | 2020-03-31 |
RS64035B1 (en) | 2023-04-28 |
JP7336434B2 (en) | 2023-08-31 |
RU2020107737A (en) | 2021-09-02 |
JP2020528922A (en) | 2020-10-01 |
CN110997681A (en) | 2020-04-10 |
RU2020107737A3 (en) | 2021-11-23 |
KR20200035439A (en) | 2020-04-03 |
AU2018309265A1 (en) | 2020-03-19 |
ZA202001295B (en) | 2023-09-27 |
PL3661941T3 (en) | 2023-05-08 |
SI3661941T1 (en) | 2023-04-28 |
BR112020001978A2 (en) | 2020-08-18 |
HUE061308T2 (en) | 2023-06-28 |
FI3661941T3 (en) | 2023-03-23 |
CA3071575A1 (en) | 2019-02-07 |
ES2940407T3 (en) | 2023-05-08 |
US20200181171A1 (en) | 2020-06-11 |
IL272284B2 (en) | 2024-01-01 |
EP3661941A1 (en) | 2020-06-10 |
EP3661941B1 (en) | 2022-12-14 |
IL272284B1 (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
ZA201705092B (en) | Substituted nucleoside derivatives useful as anticancer agents | |
GB201514875D0 (en) | Receptor | |
HK1252163A1 (en) | Receptor | |
SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
GB201717974D0 (en) | Modified receptors | |
IL277744A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist | |
SG11202000823WA (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
IL285024A (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
IL253848B (en) | Amide compounds as 5-ht4 receptor agonists | |
GB201702617D0 (en) | Receptor | |
SG11202104081XA (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
SG11202001337XA (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
EP3350167A4 (en) | Androgen receptor antagonists | |
LT3652176T (en) | Substituted xanthine derivatives | |
SG11202104078PA (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
HK1231414A1 (en) | 5-ht4 receptor agonist for gastroparesis 5-ht4 | |
EP3388423A4 (en) | Nk1 receptor antagonist | |
ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
GB201701887D0 (en) | Receptor | |
GB201700926D0 (en) | Receptor |